Please log in
to access more information


User name and Password not recognised

Home Page > The Company

The company

Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up develops and commercializes hemostatic products based on patented biopolymers designed to simplify the surgeons practices for open surgical procedures in numerous specialties such as cardiac, general and orthopedic and in laparoscopic surgeries, and give patients a better quality of life.

The Company’s lead product, HEMOBLASTTM Bellows and its laparoscopic applicator are marketed in Europe and the United States.*

Christian Gagnieu Dr. Christian Gagnieu

A Key Opinion Leader in the field of biopolymers for medical applications, Dr. Christian Gagnieu was a researcher at the INSA Lyon Engineering School and Research Manager at the Lyon Pharmacy Faculty. Dr. Gagnieu has collaborated with many companies in the medical field as an expert in biomaterials in general and in resorbable polymers in particular. Biom'up was founded on the basis of the development of his research.

Biom'up: Timeline


Exclusive distribution agreement in Australia


FDA approval for HEMOBLAST™  Bellows Laparoscopic Applicator

Submission IDE application to FDA for HEMOSNOW

Renewal of the supply agreement for human-derived thrombin for 7 years




Filing of a reimbursement dossier for HEMOBLAST™ Bellows in Australia

Completion of the scale-up of manufacturing facility

6 key manufacturing processes upgraded and approved by FDA and EMA

Exclusive distribution agreement in Spain

€7,67 million capital increase

€3 million raised bringing bond financing with Athyrium up to €28 million


CE Mark for HEMOBLAST™ Bellows Laparoscopic Applicator

First sales of HEMOBLAST™ Bellows in the US


200 surgeons and KOL trained in the US

Bond financing for €25 million with Athyrium

Finalization of commercial organization in the US


Announcement of the construction of a new production plant

€16 million capital increase




Biom’up receives FDA marketing approval for

Completion of the pivotal clinical study assessing HEMOBLAST™ Bellows in the U.S.A.

European launch

Biom’up launches its IPO on the Euronext regulated market in Paris and raise 38,1 M€


marking of HEMOBLAST Bellows

Conducting pilot study
(27 patients)

The IDE authorizes the launch of a pivotal clinical study of HEMOBLAST Bellows in humans

Inclusion of the first patient in the pivotal clinical study, prospective, randomized, multicentric clinical trial assessing the efficacy and safety of HEMOBLAST Bellows in most types of surgery

Over 150 000 medical devices implanted in Europe


IDE approval to initiate studies in human patients for HEMOBLAST Bellows

Raised 31,3 M€

Public funding COLOMATRIX


Biom’up opens two subsidiaries in the USA and in Germany


marking and launch of the COVAMESH range

Second FDA 510(k) clearance, for the COVAMESH range

Certified to ISO 13485 and ISO 9001 by the SNCH and by the BSI

logo bsi logo snch


marking and launch of the HEMOSNOW range

Second FDA 510(k) clearance, for the COVA ORTHO NERVE

Over 100 000 medical devices implanted in Europe

Raised 6,8 M€


First FDA 510(k) clearance, for the COVA MAX range


Raised 3 M€


marking and launch of the COVA and MATRI ranges


Raised 1,5 M€


Approval and development of the first OEM products


ISO 9001 and ISO 13485 certifications

logo snch


Creation of

Biom'up's Awards

Winner of the Fondation Rhône-Alpes Futur and the Innovact competition awards.
Winner of the Rhône-Alpes Entreprendre Association award and the French National Competition for Creation award in the emerging project category. Biom'up received the French high-tech mutual fund label (FCPI) and became a successful 'Start-Up'.
Winner of the National Competition for Creation award in the creation category; Novacité Labelling.